DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
GTS-21 is an investigational drug.
There have been 8 clinical trials for GTS-21. The most recent clinical trial was a Phase 2 trial, which was initiated on June 16th 2018.
The most common disease conditions in clinical trials are Tourette Syndrome, Schizophrenia, and Syndrome. The leading clinical trial sponsors are CoMentis, University of Colorado, Denver, and National Institute of Mental Health (NIMH).
Recent Clinical Trials for GTS-21
|Selective Microbiota Transplantation for Tourette's Syndrome||Faming Zhang||Phase 1/Phase 2|
|Evaluating the Efficacy and Safety of Yi-Gan San in Children and Adolescents With Tourette's Disorder||China Medical University Hospital||Phase 2|
|Effects of GTS-21 on Smoking Behavior and Neurocognitive Functions||University of Florida||Phase 2|